TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Oncopeptides AB
Closing information (x1000 SEK)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
31,648
|
36,299
|
8,355 |
| Financial expenses |
16,615
|
5,785
|
883 |
| Earnings before taxes |
-284,209
|
-248,447
|
-337,680 |
| EBITDA |
-281,027
|
-242,407
|
-332,168 |
| Total assets |
244,192
|
238,378
|
385,323 |
| Current assets |
217,081
|
202,900
|
364,034 |
| Current liabilities |
51,355
|
44,933
|
83,178 |
| Equity capital |
54,285
|
56,780
|
294,293 |
| - share capital |
23,910
|
10,511
|
10,479 |
| Employees (average) |
66
|
52
|
57 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
22.2%
|
23.8%
|
76.4% |
| Turnover per employee |
480
|
698
|
147 |
| Profit as a percentage of turnover |
-898.0%
|
-684.4%
|
-4041.7% |
| Return on assets (ROA) |
-109.6%
|
-101.8%
|
-87.4% |
| Current ratio |
422.7%
|
451.6%
|
437.7% |
| Return on equity (ROE) |
-523.5%
|
-437.6%
|
-114.7% |
| Change turnover |
-4,651
|
27,944
|
-109,940 |
| Change turnover % |
-13%
|
334%
|
-93% |
| Chg. No. of employees |
14
|
-5
|
-172 |
| Chg. No. of employees % |
27%
|
-9%
|
-75% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.